Pretzel Therapeutics Nets $72.5 Million in Series A Funding For Mitochondrial-Targeted Therapeutics

The biotech Pretzel Research has been awarded a total of $72.5 million in Series A funding. Pretzel develops therapeutics that target the mitochondria, often referred to as “the powerhouse of the cell.” There are many diseases caused by mitochondrial dysfunction and even more that are affected by it. To start, Prezel will focus on “primary” mitochondrial disorder, which affect 1 out of every 5,000 people.

According to Kyle LaHucik, “Secondary mitochondrial diseases will populate the pipeline once the thesis is proven out in initial human testing. That second batch includes the likes of Parkinson’s, Alzheimer’s, cancer and metabolic disorders, he said.”

To read more, click here.

(Source: Endpoints News, September 12^th, 2022)